Selected research
Industry Research
Exocrine Pancreatic Insufficiency Therapeutic Industry Research Report 2026
Market perspective
The global Exocrine Pancreatic Insufficiency Therapeutic market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Exocrine Pancreatic Insufficiency Therapeutic market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Exocrine Pancreatic Insufficiency Therapeutic market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Exocrine Pancreatic Insufficiency Therapeutic market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Exocrine Pancreatic Insufficiency Therapeutic include Janssen Pharmaceuticals, AbbVie, CHIESI Farmaceutici S.p.A., AzurRx and Allergan, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Exocrine Pancreatic Insufficiency Therapeutic market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Exocrine Pancreatic Insufficiency Therapeutic.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Exocrine Pancreatic Insufficiency Therapeutic Market by Company
Janssen Pharmaceuticals
AbbVie
CHIESI Farmaceutici S.p.A.
AzurRx
Allergan
Exocrine Pancreatic Insufficiency Therapeutic Segment by Type
Pancreatic Enzyme Replacement Therapy
Nutritional Therapy
Exocrine Pancreatic Insufficiency Therapeutic Segment by Application
Hospital Pharmacies
Retail Pharmacies & Drug Stores
Others
Exocrine Pancreatic Insufficiency Therapeutic Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Exocrine Pancreatic Insufficiency Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Exocrine Pancreatic Insufficiency Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Exocrine Pancreatic Insufficiency Therapeutic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Exocrine Pancreatic Insufficiency Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pancreatic Enzyme Replacement Therapy
- Nutritional Therapy
Applications
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Others
Companies covered
- Janssen Pharmaceuticals
- AbbVie
- CHIESI Farmaceutici S.p.A.
- AzurRx
- Allergan
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Exocrine Pancreatic Insufficiency Therapeutic by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Pancreatic Enzyme Replacement Therapy
- 2.2.3 Nutritional Therapy
- 2.3 Exocrine Pancreatic Insufficiency Therapeutic by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital Pharmacies
- 2.3.3 Retail Pharmacies & Drug Stores
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Exocrine Pancreatic Insufficiency Therapeutic Breakdown Data by Type
- 3.1 Global Exocrine Pancreatic Insufficiency Therapeutic Historic Market Size by Type (2021-2026)
- 3.2 Global Exocrine Pancreatic Insufficiency Therapeutic Forecasted Market Size by Type (2027-2032)
4 Exocrine Pancreatic Insufficiency Therapeutic Breakdown Data by Application
- 4.1 Global Exocrine Pancreatic Insufficiency Therapeutic Historic Market Size by Application (2021-2026)
- 4.2 Global Exocrine Pancreatic Insufficiency Therapeutic Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Exocrine Pancreatic Insufficiency Therapeutic Market Perspective (2021-2032)
- 5.2 Global Exocrine Pancreatic Insufficiency Therapeutic Growth Trends by Region
- 5.2.1 Global Exocrine Pancreatic Insufficiency Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Exocrine Pancreatic Insufficiency Therapeutic Historic Market Size by Region (2021-2026)
- 5.2.3 Exocrine Pancreatic Insufficiency Therapeutic Forecasted Market Size by Region (2027-2032)
- 5.3 Exocrine Pancreatic Insufficiency Therapeutic Market Dynamics
- 5.3.1 Exocrine Pancreatic Insufficiency Therapeutic Industry Trends
- 5.3.2 Exocrine Pancreatic Insufficiency Therapeutic Market Drivers
- 5.3.3 Exocrine Pancreatic Insufficiency Therapeutic Market Challenges
- 5.3.4 Exocrine Pancreatic Insufficiency Therapeutic Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Exocrine Pancreatic Insufficiency Therapeutic Players by Revenue
- 6.1.1 Global Top Exocrine Pancreatic Insufficiency Therapeutic Players by Revenue (2021-2026)
- 6.1.2 Global Exocrine Pancreatic Insufficiency Therapeutic Revenue Market Share by Players (2021-2026)
- 6.2 Global Exocrine Pancreatic Insufficiency Therapeutic Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Exocrine Pancreatic Insufficiency Therapeutic Head Office and Area Served
- 6.4 Global Exocrine Pancreatic Insufficiency Therapeutic Players, Product Type & Application
- 6.5 Global Exocrine Pancreatic Insufficiency Therapeutic Manufacturers Established Date
- 6.6 Global Exocrine Pancreatic Insufficiency Therapeutic Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Exocrine Pancreatic Insufficiency Therapeutic Market Size (2021-2032)
- 7.2 North America Exocrine Pancreatic Insufficiency Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Exocrine Pancreatic Insufficiency Therapeutic Market Size by Country (2021-2026)
- 7.4 North America Exocrine Pancreatic Insufficiency Therapeutic Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Exocrine Pancreatic Insufficiency Therapeutic Market Size (2021-2032)
- 8.2 Europe Exocrine Pancreatic Insufficiency Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Exocrine Pancreatic Insufficiency Therapeutic Market Size by Country (2021-2026)
- 8.4 Europe Exocrine Pancreatic Insufficiency Therapeutic Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Exocrine Pancreatic Insufficiency Therapeutic Market Size (2021-2032)
- 9.2 Asia-Pacific Exocrine Pancreatic Insufficiency Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Exocrine Pancreatic Insufficiency Therapeutic Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Exocrine Pancreatic Insufficiency Therapeutic Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Exocrine Pancreatic Insufficiency Therapeutic Market Size (2021-2032)
- 10.2 South America Exocrine Pancreatic Insufficiency Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Exocrine Pancreatic Insufficiency Therapeutic Market Size by Country (2021-2026)
- 10.4 South America Exocrine Pancreatic Insufficiency Therapeutic Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Exocrine Pancreatic Insufficiency Therapeutic Market Size (2021-2032)
- 11.2 Middle East & Africa Exocrine Pancreatic Insufficiency Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Exocrine Pancreatic Insufficiency Therapeutic Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Exocrine Pancreatic Insufficiency Therapeutic Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Janssen Pharmaceuticals
- 12.1.1 Janssen Pharmaceuticals Company Information
- 12.1.2 Janssen Pharmaceuticals Business Overview
- 12.1.3 Janssen Pharmaceuticals Revenue in Exocrine Pancreatic Insufficiency Therapeutic Business (2021-2026)
- 12.1.4 Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency Therapeutic Product Portfolio
- 12.1.5 Janssen Pharmaceuticals Recent Developments
- 12.2 AbbVie
- 12.2.1 AbbVie Company Information
- 12.2.2 AbbVie Business Overview
- 12.2.3 AbbVie Revenue in Exocrine Pancreatic Insufficiency Therapeutic Business (2021-2026)
- 12.2.4 AbbVie Exocrine Pancreatic Insufficiency Therapeutic Product Portfolio
- 12.2.5 AbbVie Recent Developments
- 12.3 CHIESI Farmaceutici S.p.A.
- 12.3.1 CHIESI Farmaceutici S.p.A. Company Information
- 12.3.2 CHIESI Farmaceutici S.p.A. Business Overview
- 12.3.3 CHIESI Farmaceutici S.p.A. Revenue in Exocrine Pancreatic Insufficiency Therapeutic Business (2021-2026)
- 12.3.4 CHIESI Farmaceutici S.p.A. Exocrine Pancreatic Insufficiency Therapeutic Product Portfolio
- 12.3.5 CHIESI Farmaceutici S.p.A. Recent Developments
- 12.4 AzurRx
- 12.4.1 AzurRx Company Information
- 12.4.2 AzurRx Business Overview
- 12.4.3 AzurRx Revenue in Exocrine Pancreatic Insufficiency Therapeutic Business (2021-2026)
- 12.4.4 AzurRx Exocrine Pancreatic Insufficiency Therapeutic Product Portfolio
- 12.4.5 AzurRx Recent Developments
- 12.5 Allergan
- 12.5.1 Allergan Company Information
- 12.5.2 Allergan Business Overview
- 12.5.3 Allergan Revenue in Exocrine Pancreatic Insufficiency Therapeutic Business (2021-2026)
- 12.5.4 Allergan Exocrine Pancreatic Insufficiency Therapeutic Product Portfolio
- 12.5.5 Allergan Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst